Berlin Pharmaceutical Industry Co., Ltd. and Acino Pharma AG (SIX: ACIN) signed a long term partnership agreement under which Berlin will market a wide range of the Swiss company’s current and future products in Thailand.

“The new products will complement our current line of therapies as well as significantly expand our presence into new areas,” said Amal Naj, Chief Executive Officer of Berlin. “We are very excited about this association with Acino and the high quality products we will bring to our patients at affordable prices,” he said.

Peter Burema, CEO of Acino Group
Peter Burema, CEO of Acino Group

Peter Burema, CEO of Acino Group, said,

“We are very pleased to partner with one of the leading pharmaceutical companies in Thailand to introduce our products in the market. We see great opportunities for our products there and rest of Asia and other emerging markets.”

Acino, based in Basle, Switzerland, specializes in the development, registration and manufacture of generic and innovative pharmaceuticals using advanced drug delivery technologies, for which it also holds patents. With a focus on solid oral dosage forms with modified release of the active ingredient, transdermal therapeutic patches and biodegradable, subcutaneous implants, Acino supplies leading pharmaceutical companies throughout Europe

Mr. Naj said the vast majority of the Acino products Berlin will introduce in Thailand are for the treatment of urological disorders, cancer and pain. The company’s current products are prescribed mainly for the treatment of cardiovascular and metabolic diseases and gastro-intestinal disorders.

Mr. Naj said a number of Acino products are innovative, and they will help strengthen Berlin’s market presence in the highly competitive market.

Berlin currently manufactures most of its products in GMP-approved (Good Manufacturing Practice) and ISO-certified facilities, and imports active pharmaceutical ingredients (API) as well as finished products from Canada, France, and India.

Berlin is one of the top 10 pharmaceutical companies in Thailand and is a market leader in many of the products it markets. The company employs 550 people.

The Acino Group is headquartered in Basle, and currently employs approximately 380 staff. Acino Holding Ltd., the Group’s parent, is listed on the SIX Swiss Exchange (SIX: ACIN).

Please note that under Thai FDA regulation, we cannot discuss individual products.


Pajasalmi, Ruangkittikul & Associates Ltd.

Khun Panarasee Thaiwatcharamas

Khun Komson Kaemthong

+662 651 8989 Ext. 222 and 441

Berlin Pharmaceutical Industry

Amal Naj, CEO

+662 652 9590

[email protected]

Acino Pharma AG

Peter Burema, CEO

+41 61 338 60 00

[email protected]

SOURCE Berlin Pharmaceutical Industry

Back to top


via Berlin Pharmaceutical and Acino Pharma of Switzerland Sign Partnership Agreement to Market a… — BANGKOK, Sept. 5, 2011 /PRNewswire/ —.

About the author

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Sign Up for Our Newsletter

Get notified of our weekly selection of news

You May Also Like

The Philippines Amends its Foreign Investment Act

The amendments aim to promote and attract foreign investments by allowing, for the first time, international investors to set up and fully own domestic enterprises (including micro and small enterprises in the Philippines.

Proposed Amendments to Thailand’s Public Limited Companies Act

The proposed amendments aim to improve the efficiency of and bring consistency to Thailand’s corporate system and procedures that were impacted by the pandemic, as borders were closed and logistics disrupted, leading to the loss in competitiveness for local businesses.

APAC region records 119% QoQ growth in M&A deal value in Q2 2022

India, Australia and China were the top three countries when measured in terms of M&A deal value in Q2, with India accounting for half of the top 20 deals. South Korea, Indonesia, Malaysia, and Japan were the next top countries that contributed to a surge in M&A deal value.